RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Lowers Price Target to $60
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Luca Issi maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and lowers the price target from $85 to $60.
RBC Capital analyst Luca Issi maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and lowers the price target from $85 to $60.